INTRODUCTION
Familial hypercholesterolaemia is a monogenic disorder associated with a greatly increased risk of coronary heart disease. 1 Statins are first choice treatment for all patients with the condition. 2 Placebo controlled trials were not carried out in these patients when statins were introduced, as it was considered unethical to withhold causal treatment from patients with an inborn error of lipid metabolism. 3 We therefore lack estimates of the true efficacy of statin treatment in such patients. The results of the atorvastatin versus simvastatin on atherosclerotic progression (ASAP) study have suggested that we should treat such patients preferably with potent statins to maximally decrease low density lipoprotein (LDL) cholesterol concentrations and induce regression of atherosclerosis. 4 5 In the recently published ENHANCE study, adding ezetimibe to the highest dose of simvastatin resulted in substantial further reductions of LDL cholesterol concentrations and high sensitivity C reactive protein levels but did not further reduce the carotid intimamedia thickness. 6 One possible explanation for these results is that patients with familial hypercholesterolaemia are currently treated optimally with statins, resulting in delipidated arterial walls of normal thickness, and, therefore, further lowering of LDL cholesterol levels has no beneficial effect. In two observational studies, secular trends suggest that statins have roughly halved the risk of coronary heart disease in patients with familial hypercholesterolaemia. 7 8 However, the exact prognosis of treated asymptomatic patients remains unknown, and this lack of hard endpoint data has, for example, limited access to life insurance. 9 In this study we investigated the effect of statins on the risk of incident coronary heart disease in patients with familial hypercholesterolaemia, using the variation in the time of starting statin treatment to mimic a clinical trial.
METHODS

Study population
During 1989-2002, we recruited a cohort of 2400 patients with familial hypercholesterolaemia from 27 lipid clinics as described previously. 10 We reviewed medical records to establish extensive phenotypic data including anthropometric measures, cardiovascular events, and use of lipid lowering drugs.
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In the present study, we chose 1 January 1990, just after the first statin (simvastatin) became available in the Netherlands, as the start point. We excluded patients who already had coronary heart disease by 1990 to mimic a controlled primary prevention trial starting at the introduction of the first statin. We determined serum lipid concentrations in fasting patients who had not used lipid lowering drugs for at least six weeks, and calculated LDL cholesterol concentrations using the Friedewald formula. 12 In addition, we compared the risk of incident myocardial infarction in patients with familial hypercholesterolaemia with that in the general population. For this analysis, we selected patients with familial hypercholesterolaemia who were older than 55 years at 1 January 1990 and a selection of the population in the Rotterdam study matched as a group for age and sex. The Rotterdam study is a large population based, prospective, follow-up study starting in 1990 assessing the disease burden in elderly people. 13 
Outcome measures
We defined coronary heart disease in our study cohort as at least one of the following:
Myocardial infarction, proved by at least two of the following: Classic symptoms (>15 minutes) Specific electrocardiographic abnormalities Elevated cardiac enzymes (>2 × upper limit of normal) Percutaneous coronary intervention or other invasive procedures Coronary artery bypass grafting Angina pectoris, diagnosed as classic symptoms in combination with at least one unequivocal result of one of the following: Exercise test Nuclear scintigram Dobutamine stress ultrasound scan >70% stenosis on a coronary angiogram.
In the Rotterdam study, no data on angina were available. We therefore chose to study myocardial infarction as the end point in this analysis. Patients with percutaneous transluminal coronary angioplasty, coronary bypass grafting, or myocardial infarction were excluded from the sample of patients from our cohort and as from the selected population from the Rotterdam study.
Statistical analysis
We compared patients' general characteristics using analysis of variance for continuous variables and χ 2 test for categorical variables. We analysed lipid concentrations, after adjustment for age and sex, with multiple linear regression analyses. We calculated absolute risk by taking into account whether statin use was started before the onset of coronary heart disease. The number of coronary events among statin treated and untreated patients was divided by the total event-free survival. Event-free survival time was defined as the period from 1 January 1990 to the date of first coronary event, death, or censoring at the end of our observation.
We also compared survival among treated and untreated patients using the Kaplan-Meier survival method. In this analysis, we considered people to be untreated when they had not taken a statin for longer than one month before a coronary event or censoring. All patients who received a statin during follow-up for more than a month before an event or censoring were considered as treated.
We performed separate analyses for patients older than 55 years to compare them with the selected population from the Rotterdam study. Since the maximum follow-up in our cohort was 12 years, we chose 2002 as the end point in the Rotterdam study as well.
We used the Cox proportional hazard model to estimate the risk of coronary heart disease among statin treated patients compared with untreated patients. Since both groups had variable periods without statin treatment, we analysed statin treatment as a time dependent variable. This variable was equal to zero for the time statins were not used, and 1 for the time from start of statin treatment to the date of first coronary event or censoring. In the primary model, we adjusted the analyses for sex and year of birth.
In additional models we adjusted for other classic risk factors (see table 2 ). We performed subgroup analyses stratified by previously identified risk factors to define effect differences. For LDL cholesterol concentration, we used the median value to split the total population in two subpopulations. We classified high density lipoprotein (HDL) cholesterol concentration according to our normal laboratory values: <0.9 mmol/l for males, <1.1 mmol/l for females. To test for lifestyle improvements occurring at the start of statin treatment, we adjusted the Cox proportional hazard model for smoking cessation within six months after the start of statin treatment. We tested whether deselection of worst cases occurred by adding the patients who were never treated with statins to the treated group as if they had started treatment on 1 January 1990 and repeated the time dependent Cox proportional hazard analysis.
RESULTS
Of the 2400 patients recruited, we excluded 254 who already had coronary heart disease by 1990. We excluded a further 188 patients because the type of lipid lowering treatment or the date of starting statin 1) . In January 1990, 413 patients were treated with a statin, and a further 1294 patients were prescribed statins during follow-up. The mean delay in starting statin use was 4.3 years (SD 3.3 years). The 196 patients who were excluded because of missing data or loss to follow-up had serum LDL cholesterol concentrations 1.14 mmol/l higher than those of the included patients. We did not find other differences between these groups.
The patients who immediately received statin treatment in 1990 were on average 3.5 years older than the patients who started statin treatment later, had higher total and LDL cholesterol concentrations (both P<0.001), had lower HDL cholesterol levels (P=0.02), and were significantly more likely to be hypertensive than the other patients (table 1) . Twenty eight patients stopped taking statins for unreported reasons.
The mean follow-up time was 8.5 years (SD 3.1 years). During 7473 person years of statin treated patients and 9319 person years of untreated patients, 408 patients had an incident coronary event, of whom 161 patients had been using statins for an average 3.4 years (median 2.7 years, range 1 month to 11.6 years). Most patients (n=1167) used simvastatin with a mean dose of 33 mg (SD 20 mg), leading to 44% (SD 16%) lower LDL cholesterol concentrations compared with before they started statin treatment. A further 211 patients used atorvastatin with a mean daily dose of 49 mg providing a reduction in LDL cholesterol level of 49% (SD 15%). Less commonly used statins were pravastatin and fluvastatin. During statin treatment the mean total cholesterol concentration was 5.9 mmol/l (SD 1.2 mmol/l), mean LDL cholesterol was 4.0 mmol/l (SD 1.2), and mean HDL cholesterol was 1.28 mmol/l (SD 0.41).
In familial hypercholesterolaemia, the absolute risk of first onset of coronary heart disease was 11/1000 person years in statin treated patients compared with 119/1000 person years in untreated patients. Incident coronary heart disease occurred at younger age in untreated patients (48.6 v 50.9 years, P=0.05). The treated group had a significantly better event-free survival (P<0.001, fig 2) . After adjustment for year of birth and sex, statin treated patients had a 76% reduction in risk of coronary heart disease compared with untreated patients (hazard ratio 0.24 (95% confidence interval 0.18 to 0.30), P<0.001). Further adjustment for baseline characteristics such as smoking, HDL and LDL cholesterol concentrations, diabetes, and hypertension resulted in an overall 82% risk reduction (hazard ratio 0.18 (0.13 to 0.25), P<0.001) (table 2) .
As expected, men had a 2.5 times greater risk of coronary heart disease than women (95% confidence interval 2.1 to 3.1, P<0.001). Whether women with familial hypercholesterolaemia benefit from statins as men do is still under debate, 14 and we therefore studied them separately. The women taking statins had a 79% reduction in risk of coronary heart disease compared with women not taking statins (hazard ratio 0.21 (0.13 to 0.34), P<0.001); the men had an 83% risk reduction (hazard ratio 0.17 (0.11 to 0.26), P<0.001) (table 2) .
Patients who developed coronary heart disease had higher serum LDL cholesterol concentrations before treatment than did those without coronary heart disease (7.5 mmol/l v 7.2 mmol/l, P=0.03). During statin treatment, however, LDL cholesterol levels were identical among patients with and without coronary heart disease (4.1 mmol/l v 4.0 mmol/l, P=0.38). Classic risk factors were, as expected, more common in patients with coronary heart disease. The subgroup analyses in fig 3 suggest that the efficacy of statin treatment did not substantially differ between smokers and non-smokers, between patients with or without diabetes, and between patients with or without hypertension. However, the size of the subgroups were too small for meaningful analyses.
Of all 1288 patients who had ever smoked, 333 had stopped before 1990. A total of 407 statin users never smoked, and 388 had stopped before statin treatment was started. A further 105 patients (10% of all those for whom smoking cessation date was known) quitted within six months of starting statin treatment. To test if lifestyle improvement related to the start of statin treatment could explain why smokers showed a larger risk reduction with statins, we adjusted for smoking cessation within six months of the start of statin treatment, but this did not materially change the effect of statin treatment on coronary heart disease risk (hazard ratio 0.20 (0.15 to 0.26), P<0.001). Unfortunately, body mass index and waist circumference were not measured during follow-up.
A total of 243 patients in our cohort were never treated with statins. We performed an additional analysis adding those patients to the treatment group, as if statin treatment had started on 1 January 1990, to estimate the effect of an intention to treat analysis. The hazard ratio was even lower under these assumptions (data not shown).
We finally compared the risk of myocardial infarction in patients with familial hypercholesterolaemia who were older than 55 years (n=261, 64 men) with that in 1975 people in a subgroup of the participants in the Rotterdam study. The mean age in both subgroups was 61.6 years and both had 24.5% men as a result of stratified selection from the Rotterdam study. The absolute risk of myocardial infarction was 6.7/1000 person years in our statin treated patients, 60.5/1000 person years in our untreated patients, and 4.1/1000 person years in the sample from the Rotterdam study. Event-free survival of our statin treated patients was not significantly different from that of the Rotterdam study sample (log rank test P=0.07), whereas our untreated patients clearly had a higher risk of coronary heart disease (log rank test P<0.001) (fig 4) . After adjustment for year of birth and sex, the point estimate of risk of myocardial infarction in our treated patients with familial hypercholesterolaemia was higher than the risk in the subgroup of the Rotterdam study, but this was not significant (hazard ratio 1.44 (0.80 to 2.60), P=0.23), whereas the risk in our untreated patients was 8.7 times higher (hazard ratio 8.69 (4.77 to 15.82), P<0.001).
DISCUSSION
We report here that relatively modest doses of statins reduced the risk of coronary heart disease by about 80% in patients with familial hypercholesterolaemia. This is a much more pronounced reduction than was anticipated based on secular trends in earlier studies. 7 8 We also observed that statin treated patients older than 55 years had a risk of myocardial infarction approaching that of the general population. Finally, men and women experienced similar risk reductions in our study.
Strengths and weaknesses of our study Our follow-up study has a number of limitations. Firstly, it was observational and not a randomised study. Therefore, the patients who started treatment immediately in 1990 may have represented a selected subgroup with more severe risk: they were selected first because they had further progressed in their disease process. If this were so, it would have resulted in a higher risk for the treated group compared with a randomised trial that distributed the risks equally. However, it seems unlikely that we have underestimated the risk reduction as the effect was unexpectedly large.
Secondly, it could be argued that our approach exaggerates the effect of the treatment, because our study was not placebo-controlled. Patients might have improved their lifestyle in conjunction with starting statin treatment. However, adjustment for smoking cessation within six months after the start of treatment (as a proxy for lifestyle improvement) did not change the effect of statin treatment. Thirdly, we analysed statin treatment as a time dependent variable, whereas an intention to treat analysis might have yielded smaller risk reductions. We analysed the 28 patients who stopped statin treatment as if they had stayed on treatment, in line with an intention to treat analysis. We also made an analysis in which all patients who were never treated with statins were added to the treated group as if they had started treatment on 1 January 1990, to estimate the effect that an intention to treat analysis could have had: this showed an even larger effect. Although this value is a rough estimation sensitive to choice of date of start of treatment, the decrease in hazard ratio indicates that our results are not overestimating the effect as a result of deselection of worst cases.
Although some of the weaknesses associated with lack of randomisation have been addressed, there is always the danger that unrecognised confounding factors, for which we made no adjustment, might have affected our results.
Comparison with other studies The large risk reduction and the overlap of the eventfree survival between the treated patients and a sample of the general population (from Rotterdam study) suggest that statin treatment has profoundly improved the prognosis for familial hypercholesterolaemia.
Two previous studies have investigated this issue. A study in the United Kingdom compared mortality in patients with familial hypercholesterolaemia with that in the general population before and after the introduction of statins. 7 Their results suggested that statins did indeed reduce mortality, but that mortality was still higher than in the general population. Exact information about the start date of statin treatment was not available, however, suggesting there might have been an unrecognised delay in statin initiation similar to what we found in the Netherlands.
In a much smaller study, 214 statin treated patients with familial hypercholesterolaemia still had increased risk of cardiovascular disease. 8 As suggested by the high frequency of premature cardiovascular disease (45%) in first degree relatives, the patients of this study might have been selected preferentially for severe risk of coronary heart disease. Moreover, statin treatment was not assessed against untreated familial hypercholesterolaemia and not in a time dependent fashion. The latter may have resulted in underestimation of the statin effect because of misclassification of periods without treatment. In contrast, in our study, we prospectively compared treated and untreated patients with familial hypercholesterolaemia as well as the general population in a direct manner and in the same calendar period.
Implications of findings
The standard treatment used currently is more aggressive than that used in our study: current regimens use simvastatin and atorvastatin doses up to 80 mg daily. 2 4 It should be emphasised, however, that in our study we excluded all prevalent cases, thereby restricting our study to primary prevention. Our results cannot be extrapolated to secondary prevention, which may require more aggressive treatment.
Support for optimal treatment with statins can also be deduced from the results of the ENHANCE study: patients with familial hypercholesterolaemia had normal carotid intima-media thickness at baseline, and even simvastatin 80 mg alone prevented thickening of the arterial wall. 6 In previous studies we tested statin treatment of children with familial hypercholesterolaemia and showed attenuation of progression of carotid intimamedia thickness. 15 16 Our present study suggests that starting aggressive treatment during early childhood, as currently done and advised by the American Academy of Pediatrics, is probably not necessary to reduce coronary heart disease risk. 17 Although atherosclerosis is present in children, this process is to a certain extent reversible, as shown by the close to normal intima-media thicknesses at baseline in the ENHANCE trial and our findings in the present study. In both studies, statin treatment was initiated after childhood. It is probably safe to limit statin treatment of children with heterozygous familial hypercholesterolaemia to those whose 
WHAT IS ALREADY KNOWN ON THIS TOPIC
Statins are the first line treatment for familial hypercholesterolaemia, but their efficacy is unknown because hard end points were not studied in placebo controlled trials
WHAT THIS STUDY ADDS
Lower statin doses than currently advised reduced coronary heart disease risk by 80% in patients with familial hypercholesterolaemia Statin treated patients older than 55 years had a similar risk of myocardial infarction as did a sample from the general population of the same age first degree relatives have severe premature coronary heart disease.
In conclusion, our data show that lower statin doses than currently advised result in impressive reductions of coronary heart disease risk in patients with familial hypercholesterolaemia. These findings warrant an immediate start of statin treatment after familial hypercholesterolaemia has been diagnosed since such treatment leads to near normalisation of coronary heart disease risk.
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